> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Tzield as First Drug to Delay Type 1 Diabetes, Using 14-Day Infusion Before Clinical Disease
- URL: https://www.theamericanquorum.com/taq-historical-2022-11-19-healthcare/
- Published: 2022-11-20T04:59:00.000Z
- Updated: 2022-11-20T04:59:00.000Z
- Description: FDA approved Tzield to delay progression from stage 2 to stage 3 type 1 diabetes in adults and children 8 and older, making it the first treatment approved to postpone clinical onset.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare, #Import 2026-08-31 18:59

The Food and Drug Administration approved Tzield, or teplizumab-mzwv, on Thursday as the first therapy designed to delay the onset of clinical type 1 diabetes in people who have already entered an earlier, presymptomatic stage of the disease. The approval covers adults and children ages 8 and older with stage 2 type 1 diabetes and uses a once-daily intravenous infusion for 14 consecutive days, according to the FDA’s [Drug Trials Snapshot](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-tzield?ref=theamericanquorum.com).

The decision changes the treatment objective for a subset of people at very high risk. Until now, type 1 diabetes care has largely begun after the immune system has destroyed enough insulin-producing beta cells to produce clinical hyperglycemia and require lifelong insulin. Tzield is intended for people who have not yet reached that point but already have evidence of autoimmune attack and abnormal glucose regulation. The therapy does not cure type 1 diabetes and does not guarantee that clinical disease will never develop; its purpose is to delay the transition.

## The approval depends on identifying disease before symptoms

The pivotal study enrolled 76 participants ages 8 to 49 who were relatives of people with type 1 diabetes and met criteria for high risk. The trial record, [NCT01030861](https://clinicaltrials.gov/study/NCT01030861?ref=theamericanquorum.com), describes participants as autoantibody-positive, nondiabetic relatives with impaired glucose tolerance. Researchers randomly assigned them to teplizumab or placebo and followed them for progression to clinical diabetes.

That design reflects an important change in how researchers understand type 1 diabetes. The disease can be staged before the classic symptoms of excessive thirst, frequent urination, weight loss or diabetic ketoacidosis appear. Stage 1 includes multiple islet autoantibodies with normal glucose regulation. Stage 2 adds dysglycemia but still lacks symptomatic diabetes. Stage 3 is the point at which glucose abnormalities meet diagnostic criteria for clinical disease.

Because Tzield is approved at stage 2, its practical use depends on finding people who do not yet feel ill. That generally means screening relatives or other high-risk individuals for islet autoantibodies and confirming abnormal glucose tolerance. The therapy therefore links drug treatment to a screening infrastructure that is not part of routine care for most Americans.

## A 2019 trial showed a roughly two-year median delay

The central evidence emerged from the National Institutes of Health-supported Type 1 Diabetes TrialNet. In 2019, NIH reported that a single course of teplizumab delayed the median time to clinical type 1 diabetes by about two years in high-risk participants. The [June 2019 announcement](https://www.nih.gov/news-events/news-releases/drug-delays-type-1-diabetes-people-high-risk?ref=theamericanquorum.com) described the study as the first to demonstrate that clinical type 1 diabetes could be delayed in people at high risk.

The original peer-reviewed results, published in the [New England Journal of Medicine](https://www.nejm.org/doi/abs/10.1056/NEJMoa1902226?ref=theamericanquorum.com), found that 57% of participants receiving teplizumab remained free of clinical diabetes at the end of the initial trial period, compared with 28% of those receiving placebo. The median time to diagnosis was approximately 48 months in the teplizumab group and 24 months in the placebo group. Rash and transient lymphopenia were among the adverse events observed.

Those results were notable not simply because a drug changed a laboratory marker, but because it shifted the timing of a clinically consequential diagnosis. For a child, an additional period without insulin injections, glucose monitoring and the daily management burden of type 1 diabetes can be meaningful even if disease eventually develops.

## Longer follow-up suggested the effect persisted

Researchers continued following the trial participants after the original publication. A 2021 [NIH analysis](https://www.nih.gov/news-events/nih-research-matters/drug-delays-type-1-diabetes-onset?ref=theamericanquorum.com) reported an average time to diagnosis of 59.6 months among teplizumab-treated participants compared with 27.1 months for placebo. At that later point, 50% of treated participants remained diabetes-free versus 22% of untreated participants. The follow-up also found evidence that insulin production was better preserved in the treatment group.

The mechanistic follow-up was published in [Science Translational Medicine](https://www.science.org/doi/10.1126/scitranslmed.abc8980?ref=theamericanquorum.com). Teplizumab is an anti-CD3 monoclonal antibody that acts on T cells, the immune cells involved in attacking pancreatic beta cells in type 1 diabetes. The treatment is not broadly eliminating the immune system; it is intended to alter the autoimmune process sufficiently to preserve beta-cell function for longer.

TrialNet, the NIH-supported network that conducted the prevention study, called Thursday’s decision the culmination of years of screening and prevention research. Its [teplizumab study summary](https://www.trialnet.org/our-research/completed-studies/teplizumab?ref=theamericanquorum.com) notes that TrialNet collected risk data from more than 200,000 relatives of people with type 1 diabetes over two decades, helping establish the staging system that makes an intervention before clinical diagnosis possible.

## The benefit must be weighed against infusion burden and immune effects

Tzield is not a simple one-time injection. Patients receive an intravenous infusion each day for 14 days, creating logistical demands for families and treatment centers. The FDA also identifies important safety concerns associated with immune modulation, including cytokine-release syndrome, serious infections, lymphopenia and hypersensitivity reactions. Vaccination status and active infections therefore matter when clinicians consider treatment.

The approval also raises questions about access. A therapy aimed at stage 2 disease can benefit only people who know they are at high risk and can obtain confirmatory testing. Relatives of people with type 1 diabetes have been the focus of TrialNet screening, but many people who eventually develop type 1 diabetes do not have a known first-degree relative with the condition. Broader screening would require new clinical pathways, cost decisions and evidence about whom to test.

Still, the regulatory milestone is distinct from another glucose-lowering medicine. Tzield is the first approved therapy intended to alter the timeline of type 1 diabetes before symptomatic disease emerges. The FDA’s decision validates a prevention-oriented strategy that researchers have pursued for decades: identify autoimmune diabetes before beta-cell loss becomes clinically irreversible, then intervene early enough to preserve function.

The limits are equally important. Tzield delays stage 3 disease; it has not been shown to prevent type 1 diabetes permanently. The pivotal trial is small compared with many common chronic-disease trials, and the treatment requires specialized infusion and monitoring. But for people who meet the stage 2 criteria, the approval creates a treatment option where none previously existed. It also moves type 1 diabetes care into a new phase in which diagnosis, risk prediction and treatment can begin before the first symptoms appear.